$-0.95 EPS Expected for ESSA Pharma Inc. (EPI)

July 14, 2018 - By Elizabeth Jones

Analysts expect ESSA Pharma Inc. (CVE:EPI) to report $-0.95 EPS on August, 13.They anticipate $3.45 EPS change or 78.41 % from last quarter’s $-4.4 EPS. After having $-1.05 EPS previously, ESSA Pharma Inc.’s analysts see -9.52 % EPS growth. The stock decreased 1.57% or $0.08 during the last trading session, reaching $5. About 500 shares traded. ESSA Pharma Inc. (CVE:EPI) has 0.00% since July 14, 2017 and is . It has underperformed by 12.57% the S&P500.

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on the development of novel therapeutics for the treatment of prostate cancer. The company has market cap of $28.88 million. It is developing EPI-506 that is in Phase 1/2 clinical trials for the treatment of prostate cancer. It currently has negative earnings.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.